ITBMed AB
Major Drugs - N/A, N/A, SE
ITBMed AB Details
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics primarily for organ transplantation and stem cell transplantation. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in revolutionizing the treatment of organ transplant patients, by allowing the complete discontinuation of all immunosuppressive drugs and restoration of a normal life.
Website:
itb-med.com
Employees:
20 - 49
HQ:
N/A
Location:
N/A, N/A, SE
Revenue:
1 - 2.5 Million
ITBMed AB Technologies
Email Providers
Outlook
Load Balancers
Nginx
Tag Management
Google Tag Manager
Other
Mobile Friendly
CSS and JavaScript Libraries
Bootstrap Framework